Precision neuropsychiatry spotlight: a BioCentury podcast
Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry
Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals Inc.’s $14 billion takeout by Bristol Myers Squibb Co. (NYSE:BMY) and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise of precision medicine in the space and break down what recent setbacks for key players mean for next steps in the clinic. The team is joined by special guest Peter Schueler, SVP of drug development solutions, neurosciences, at Icon plc (NASDAQ:ICLR), who delivers takeaways from this month’s the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt, and a recent white paper by Icon.
This episode of the BioCentury This Week podcast was sponsored by Icon Biotech. Download Icon’s free white paper at www.ICONplc.com/CNStrials
BCIQ Company Profiles
BCIQ Target Profiles